Interested in how you can get involved with Pharma & Biotech Patent Litigation 2025?
Based on your objectives, we can create bespoke packages for you. From presenting your expertise on stage to partnering with us to deliver networking activities. Partner with us in 2025 to showcase your brand and make valuable new connections. Opportunities include thought leadership, branding, and networking.
Discuss your objectives with Duncan Henderson, Commercial Partnerships Director, [email protected]
Loading videos...
Platinum Partners
Linklaters
Website: https://www.linklaters.com/
Linklaters cross-border Intellectual Property team successfully advises market-leading companies on high-profile IP litigation and complex IP-driven transactions.
We advise clients in a broad range of sectors, with a focus on IP-heavy industries such as healthcare and life sciences.
Our history of advising clients in the healthcare and life sciences sector is long and we have developed strong working relationships and a deep understanding of our client’s business environment. Many of our lawyers have technical backgrounds and therefore have in-depth understanding of complex technologies.
We support our clients with outstanding legal skills, expert sector knowledge and a pragmatic mindset in cross-border IP disputes. More specifically our litigation practice covers the full scope of dispute resolution, including court proceedings, arbitration, mediation and settlement discussions. Where possible, we aim to resolve disputes before court proceedings become necessary. However, where litigation is unavoidable, we take care to pick the right cases to pursue through the courts and continue to look for pragmatic solutions.
We tackle the entire spectrum of IP rights, including patents, supplementary protection certificates, copyrights, designs and trademarks. Our practice also covers issues of confidentiality, as well as trade secrets protection and misappropriation.
Gold Partners
Carpmaels & Ransford
Website: https://www.carpmaels.com/
Carpmaels & Ransford LLP is a leader in the European IP market, having driven innovation in the industry for over 200 years. The firm advises clients on all aspects of intellectual property, including drafting, filing and prosecuting patent and trademark applications; drafting and negotiating licence agreements and other commercial IP agreements; advising on the transfer of property rights; assisting clients with patent restoration matters; and conducting enforcement and revocation litigation.
The firm has one of Europe’s largest IP teams serving blue-chip clients across the globe, including Johnson & Johnson, Bristol Myers Squibb, Novartis, Ionis Pharmaceuticals, Mars, Gilead, Raytheon, Regeneron, Takeda, Allergan and Xeros. The firm’s attorneys have considerable technical knowledge, bringing together experience from industry-leading companies, academic research at leading universities and extensive patent expertise in the areas of pharmaceuticals, biotechnology, engineering, tech, chemistry, materials, supplementary protection certificates and information and communication technologies and standards.
Through its fully integrated dispute resolution and transactions teams, the firm is able to provide a holistic service to clients which supports their IP needs from inception to commercialisation. The dispute resolution team, made up of experienced solicitors, barristers and patent attorney litigators, represents clients at all levels of the European Patent Office. The team is also adept at conducting enforcement litigation and revocation actions before the UK Intellectual Property Office and patent, copyright, trademark and other IP litigation in the English courts and the Court of Justice of the European Union, often advising in cases where parallel or related litigation is ongoing in courts across Europe or in the United States.
As a European IP firm with litigators and patent attorneys under one roof, Carpmaels & Ransford is looking forward to offering clients the chance to both obtain UPs using the existing EPO procedure and enforce their patents across Europe in the UPC.